FindTrial
Sign In

5-fluoruracil

DRUG8 trials

Sponsors

Hellenic Oncology Research Group, Federal University of São Paulo, Lund University Hospital, Hoffmann-La Roche, Grupo Espanol Multidisciplinario del Cancer Digestivo

Conditions

Actinic KeratosisBreast CancerGastric CancerInflammatory Breast CancerInvasive Ductal Breast CancerLocally Advanced Cancer in the Anal RegionMucinous Breast CancerPhotoaging

Phase 1

Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0
CompletedNCT01621217
Lund University HospitalLocally Advanced Cancer in the Anal Region
Start: 2012-06-30End: 2020-01-31Target: 21Updated: 2020-02-28

Phase 2

Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer
CompletedNCT02340949
Grupo Espanol Multidisciplinario del Cancer DigestivoRectal Cancer
Start: 2015-01-31End: 2020-02-04Updated: 2021-05-03

Phase 3

Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer
CompletedNCT00431080
Hellenic Oncology Research GroupBreast Cancer
Start: 2004-08-31End: 2007-10-31Updated: 2008-01-21
Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer
CompletedNCT00615602
Hellenic Oncology Research GroupBreast Cancer
Start: 2004-10-31End: 2012-05-31Updated: 2015-03-04
5fluorouracil for Advanced Photoaging
NCT01405144
Federal University of São PauloActinic Keratosis, Photoaging
Start: 2010-08-31End: 2012-03-31Target: 30Updated: 2011-07-29
A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer
CompletedNCT01662869
Hoffmann-La RocheGastric Cancer
Start: 2012-11-30End: 2015-12-31Updated: 2016-11-02
Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer
CompletedNCT01985724
Hellenic Oncology Research GroupBreast Cancer
Start: 2007-10-31End: 2013-12-31Updated: 2014-05-14
Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy
NCT02879513
RenJi HospitalInflammatory Breast Cancer, Invasive Ductal Breast Cancer, Mucinous Breast Cancer +1
Start: 2014-01-31End: 2022-12-31Target: 290Updated: 2020-03-23

Related Papers

Randomized phase II trial of modified (m) FOLFOX6 induction chemotherapy with or without aflibercept before standard chemoradiotherapy (CRT) and total mesorectal excision (TME) in patients with high-risk rectal adenocarcinoma (HRRC): Final results of the GEMCAD 1402, and by molecular subtypes.
Journal of Clinical Oncology2020-05-208 citations
Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma
JAMA Oncology2019-08-2947 citations
Dissecting gastric cancer biology and how and when to use immunotherapy
Annals of Oncology2018-10-01
RIA: Randomized phase II study comparing induction (I) mFOLFOX6 with or without aflibercept followed by chemoradiation (CRT) and total mesorectal excision (TME) in high risk-rectal cancer. GEMCAD 14-02 trial.
Journal of Clinical Oncology2018-05-203 citations
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma
JAMA Oncology2016-12-05292 citations
METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC).
Journal of Clinical Oncology2015-05-20102 citations
Induction mFOLFOX6 with or without aflibercept followed by chemoradiation (CRT) and surgery in high risk rectal cancer: Phase II randomized, multicenter, openlabel trial—The GEMCAD RIA study.
Journal of Clinical Oncology2015-05-20
Randomized phase II study of FOLFOX +/- MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC).
Journal of Clinical Oncology2015-01-2041 citations
False-negative rate for HER2 testing in 738 gastric and gastroesophageal junction cancers (GEC) from two global randomized clinical trials.
Journal of Clinical Oncology2015-01-2015 citations
Effects of varied magnesium supply on wheat grown under ambient and elevated carbon dioxide conditions
2014-11-04
A multicenter randomized study comparing 6 versus 12 months of trastuzumab in combination with dose-dense docetaxel following FEC as adjuvant treatment of women with axillary node–positive or high-risk, node-negative breast cancer overexpressing HER2.
Journal of Clinical Oncology2014-05-201 citations